Stay updated with breaking news from Anthonyw tolcher. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ Vial has added NEXT Oncology to their Preferred Site Network (PSN). Founded by renowned oncologist Dr. Anthony W. Tolcher, NEXT Oncology is a. ....
/PRNewswire/ IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and. ....
SAN DIEGO and SUZHOU, China, Jan. 27, 2022 Adagene Inc. , a company transforming the discovery and development of novel antibody-based therapies, today announced the first patient has been. | January 27, 2022 ....
Share this article Share this article SUZHOU, China, July 14, 2021 /PRNewswire/ Transcenta Holding Limited ( Transcenta ), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the first US patient has been dosed in the global Phase I clinical trial of PD-L1/TGF-β bi-functional antibody TST005. TST005 is the second bi-functional anti-PD-L1 and TGF-β trap fusion protein entering the global clinical stage. It simultaneously targets two immuno-suppressive pathways, transforming growth factor -β (TGF-β) and programmed cell death ligand-1 (PD-L1), that are commonly used by cancer cells to evade the immune system. TST005 consists of a high affinity PD-L1 antibody fused with an engineered TGF-β Receptor Type II protein in its C-terminal. TST005 lacks FcR binding activity and thus has reduced FcR mediated killing of PD-L1 expressing effector T cells. T ....
Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline News Provided By Share This Article /EIN News/ PALO ALTO, Calif., April 01, 2021 (GLOBE NEWSWIRE) Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced the formation of its Scientific Advisory Board (SAB) composed of world leading academics and industry leaders in cancer research and therapeutics. John C. Byrd, M.D., will serve as Chairman of the SAB. “The Vincerx team is thrilled to welcome globally recognized key opinion leaders in hematologic malignancies and oncology drug development to our newly formed SAB,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. “Their collective expertise aligns with the advancement of our diversified oncology pipeline and will be critical as we expand our research and developmen ....